CLINICAL TRIAL: PHASE 1 CLINICAL TRIAL OF DAILY ORAL GLEEVE AND ONE HOUR WEEKLY

临床试验：每日口服手套和每周一小时的第一阶段临床试验

• 批准号: 7951970
• 负责人: JOHN L. MARSHALL
• 金额: $ 2.42万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951970
• 关键词: Anaphase; Angiogenesis Inhibitors; Antineoplastic Agents; Antitumor Response; Biopsy; Cancer Patient; Cell Cycle; Cell Proliferation; Chronic Myeloid Leukemia; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Dose-Limiting; Drug Kinetics; Funding; Gastrointestinal Stromal Tumors; Gleevec; Grant; Hour; Institution; Maximum Tolerated Dose; Metaphase; Microtubule Stabilization; Microtubules; Mitotic; New Agents; Non-Small-Cell Lung Carcinoma; Oral; Paclitaxel; Pathway interactions; Patients; Phase I Clinical Trials; Platelet-Derived Growth Factor Receptor; Protein Tyrosine Kinase; Refractory; Research; Research Personnel; Resources; Safety; Secondary to; Source; Taxane Compound; Toxic effect; United States National Institutes of Health; chemotherapy; cohort; depolymerization; malignant breast neoplasm; preclinical study; receptor expression; response; taxane; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Gleevec has shown activity in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors via potent activity against Bcr-Abl, platelet-derived growth factor receptor, and the C-Kit activated tyrosine kinase pathway. Paclitaxel has broad antitumor activity on microtubules via its action on microtubular assembly and stabilization of the microtubules against depolymerization, thereby inhibiting cellular proliferation by inducing a sustained mitotic block at the metaphase-anaphase portion of the cell cycle. Previous preclinical studies have shown significant synergistic effects when other chemotherapy agents have been combined with Gleevec, however Paclitaxel has not been evaluated in such a comparison. By combining the broad acting agent Paclitaxel with the new agent Gleevec we may observe additive or even synergistic effects without significant increases in toxicities secondary to independent antineoplastic mechanisms \par \par SPECIFIC AIMS: \par Primary Aims: \par +\tab Determine the dose-limiting toxicity and maximum tolerated dose of Gleevec and Paclitaxel when given in combination to patients with advanced tumors. \par +\tab Characterize the pharmacokinetics of Gleevec and Paclitaxel when given in combination. \par \par Secondary Aims: \par +\tab Document any objective antitumor response in patients treated with Gleevec and Paclitaxel. \par +\tab Document the relationship between C-Kit and platelet derived growth factor receptor (PDGF-R) expression on tumor biopsies and tumor response to the combination of Gleevec and Paclitaxel. \par \par Additional Cohort Objectives: \par +\tab Document any relationship between C-Kit and PDGF-R expression on tumor biopsies and tumor response to Gleevec and Paclitaxel in Taxane refractory breast cancer patients. \par +\tab Document any relationship between C-Kit and PDGF-R expression on tumor biopsies and tumor response to Gleevec and Paclitaxel in Taxane refractory Non-Small Cell Lung Cancer patients. \par \par Hypothesis: To determine the safety of combining these two potential anti-angiogenic agents.

这个子项目是众多研究子项目之一